NCT05259189 is a Phase 1 clinical trial of NBL-012 Injection in Healthy Subjects, sponsored by NovaRock Biotherapeutics, Ltd.

Who is sponsoring NCT05259189?

NCT05259189 is sponsored by NovaRock Biotherapeutics, Ltd.

What drugs are being tested in NCT05259189?

Interventions in NCT05259189: NBL-012 Injection, Placebo.

What condition does NCT05259189 study?

NCT05259189 studies Healthy Subjects.

Is NCT05259189 still recruiting?

NCT05259189 is currently completed. Last updated 20 July 2022.

Last reviewed 2022-07-20 · How we verify

NCT05259189

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of NBL-012 in Healthy Chinese Subjects

Completed Phase 1 Last updated 20 July 2022

What this trial tests

Phase 1 trial testing NBL-012 Injection in Healthy Subjects in 52 participants. Completed in 23 May 2022.

Timeline

1 July 2021

Primary endpoint
23 May 2022

23 May 2022

Quick facts

Lead sponsor	NovaRock Biotherapeutics, Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	52
Start date	1 July 2021
Primary completion	23 May 2022
Estimated completion	23 May 2022
Sites	1 location across China

Drugs / interventions tested

NBL-012 Injection — full drug profile →
Placebo

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

NovaRock Biotherapeutics, Ltd — full company profile →

Who can join

Adults 18 to 45, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the safety, tolerability and pharmacokinetics (PK) of NBL-012 as single ascending doses (SAD) administered subcutaneously to healthy Chinese subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05259189 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NovaRock Biotherapeutics, Ltd
Last refreshed: 20 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05259189.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing